STEAM-MAP 1 Study - Steam Therapy With MRI and AI-assisted Planning

Starting soon · Not applicable

Conditions studied: Benign Prostatic Hyperplasia (BPH)

In brief

The STEAM-MAP 1 Study is a single-arm, prospective feasibility trial evaluating the integration of MRI-transrectal ultrasound (TRUS) fusion guidance into Rezūm water vapor thermal therapy for men with symptomatic benign prostatic hyperplasia (BPH).

Key facts

Study ID

NCT07663344

Run by

Chinese University of Hong Kong

People needed

15

Starts

2026-06-01

Expected to finish

2028-03-31

Last updated by the study team

2026-06-23

Who can join

Age: 30 and older, up to 80. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Age 30-80 years old with symptomatic BPH.
• Prostate volume 30-80 mL (TRUS/MRI/US)
• Suitable for Rezum.
• Able to consent and comply with follow-up to 1 month.
• With prior prostate MRI within 2 years

You may not qualify if…

• Known/suspected prostate cancer requiring oncologic management.
• Prior prostate surgery impacting urethral anatomy within 12 months.
• Prior implant affecting urethral anatomy.
• Active UTI or untreated bacteriuria pre-op.
• Uncorrectable coagulopathy; inability to manage antithrombotics.
• Severe medical comorbidity precluding endoscopy.

Where it is running

• Prince of Wales Hospital — Shatin, Hong Kong
• North District Hospital — Sheung Shui, Hong Kong
• Alice Ho Miu Ling Nethersole Hospital — Tai Po, Hong Kong

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.